Cargando…
HGG-09. FIRST LINE THERAPY OF PEDIATRIC GLIOBLASTOMA WITH LAROTRECTINIB
PURPOSE: In this case report, we document new recommendations for the treatment of pediatric glioblastoma based on a genetic understanding of the disease. PATIENTS AND METHODS: A Saudi girl aged 18 months presented with a history of right sided weakness and partial seizures. MRI revealed the presenc...
Autores principales: | Alharbi, Musa, Mobark, Nahla Ali, Balbaid, Ali Abdullah O, Alanazi, Fatmah A, Aljabarat, Wael Abdel Rahman, Bakhsh, Eman A K, Turkistani, Murad, Abedalthagafi, Malak |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715190/ http://dx.doi.org/10.1093/neuonc/noaa222.299 |
Ejemplares similares
-
Regression of ETV6-NTRK3 Infantile Glioblastoma After First-Line Treatment With Larotrectinib
por: Alharbi, Musa, et al.
Publicado: (2020) -
HGG-18. Long-term efficacy and safety of larotrectinib in paediatric patients with tropomyosin receptor kinase (TRK) fusion-positive primary central nervous system (CNS) tumours
por: Nysom, Karsten, et al.
Publicado: (2022) -
HGG-09. MicroRNAs expression profile in Meningioma 1 (MN1) gene altered astroblastoma
por: Antonelli, Manila, et al.
Publicado: (2022) -
HGG-09. TARGETING FACILITATES CHROMATIN TRANSCRIPTION (FACT) AS A NOVEL STRATEGY THAT ENHANCES RESPONSE TO HISTONE DEACETYLASE (HDAC) INHIBITION IN DIPG
por: Ehteda, Anahid, et al.
Publicado: (2021) -
HGG-36. ONC201 TARGETING IN DIPG
por: Abuarqoub, Alqassem, et al.
Publicado: (2021)